

4DMedical expands patient access to functional lung imaging with Integral Diagnostics contract

30 October 2023

Highlights

- Contract expands patient access to 4DMedical's XV Technology® through a leading provider of medical imaging services across Australia and New Zealand
 - Initial pilot will commence immediately at two clinical sites in Ballarat, Victoria, and enable Integral Diagnostics to offer 4DMedical's XV LVAS® and CT LVAS™ products to referring clinicians
 - Network-wide rollout will include joint marketing and engagement campaign
-

Melbourne, Australia, 30 October 2023: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the signing of a distribution agreement with Integral Diagnostics (ASX:IDX), a leading supplier of medical imaging services across Australia and New Zealand.

Distribution network expansion with phased rollout

With a network spanning 71 sites across Victoria, regional New South Wales, Queensland and Western Australia, this agreement has the potential to significantly expand patient access to 4DMedical's unique XV Technology®-enabled ventilation reports.

The initial phase of this relationship commences with two Integral Diagnostics clinical sites at Ballarat in regional Victoria, providing a basis for further expansion of proven systems and processes.

Preceding a network-wide rollout, a marketing and engagement campaign is to be jointly formulated and initiated by the two companies, building awareness and understanding amongst audiences of referring clinicians as distribution reach and patient catchment areas are expanded.

Widened access to multiple product lines

Signing of this agreement enables Integral Diagnostics to offer 4DMedical's core XV Technology® products, delivered using a Software-as-a-Service (SaaS) automated workflow. Access to both fluoroscopy-enabled XV LVAS® software and computed tomography (CT)-based CT LVAS™ software are covered in the agreement, which will enable a wider cohort of patients to access insights available only through 4DMedical-developed technologies.

Potential international expansion

Integral Diagnostics' recent acquisitions of 20 imaging clinics in New Zealand, centred in Auckland, provides a potential longer-term conduit for the first trans-Tasman availability of 4DMedical's unique XV Technology®.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com

**4DMedical MD/CEO and Founder Andreas Fouras said:**

The synergies between 4DMedical and distribution partner Integral Diagnostics are meaningful. Both companies share a culture of patient-centricity, improving outcomes through evidence-based care, a desire to innovate and improve healthcare practices, and a model of creating value for a diverse audience of stakeholders.

This agreement announced today means more patients and clinicians, particularly in regional Australia, will gain access to insights that only our proven XV Technology® can deliver. Commencing with operations in Ballarat demonstrates a commitment to increase the accessibility of XV Technology® and a commitment to improve healthcare across the regions.

A joint approach to marketing and engagement prior to rollout reflects a collective undertaking to inform our client base and create demand for our shared product offering. I am delighted that 4DMedical is working with Integral Diagnostics to expand the availability of advanced respiratory imaging to more people.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts**Corporate**

Chief Financial Officer

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

The Capital Network (TCN)

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) - the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing clinical imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.